GlassScriptPhysician profile
Matthew L Picone
NPI 1346262508
$899.22
in general payments reported to CMS, 2019-2025
22 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.32 · 2020: $22.57 · 2022: $85.12 · 2023: $212 · 2024: $339 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $140.03 | 2022-2025 | |
| Abbvie INC. | $127.35 | 2023-2025 | |
| Novo Nordisk INC | $103.38 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $67.24 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Lundbeck LLC | $58.16 | 2024 | Rexulti |
| Exact Sciences Corporation | $52.82 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $49.37 | 2019-2020 | |
| Axsome Therapeutics, INC. | $32.44 | 2022-2025 | Auvelity |
| Glaxosmithkline, LLC. | $24.58 | 2019-2025 | Trelegy Ellipta |
| Dexcom, INC. | $23.42 | 2024 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $22.42 | 2024 | Aptima |
| Gilead Sciences, INC. | $20.64 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.01 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.87 | 2024 | |
| Astellas Pharma US INC | $19.26 | 2025 | Veozah |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $18.96 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $18.66 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $17.60 | 2024 | Gattex |
| Merck Sharp & Dohme LLC | $17.08 | 2024 | Gardasil 9, Gardasil |
| Sumitomo Pharma America, INC. | $16.35 | 2024 | Gemtesa |
| Seqirus USA INC | $16.24 | 2025 | Flucelvax, Fluad |
| Astrazeneca Pharmaceuticals LP | $13.34 | 2024 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Picone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.